Sarepta (SRPT) +11.5% to $12.02 after a positive weekend article in Barrons about the company's Eteplirsen treatment for Duchenne muscular dystrophy, which could receive expedited approval from the FDA if its Phase IIb trials are as strong as earlier studies. One analyst has a price target of $16 and reckons peak sales could hit $600M; however, writing on The Street, Nathan Sadeghi-Nejad remains cautious.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs